BR0206251A - Métodos para avaliar e tratar leucemia - Google Patents

Métodos para avaliar e tratar leucemia

Info

Publication number
BR0206251A
BR0206251A BR0206251A BR0206251A BR0206251A BR 0206251 A BR0206251 A BR 0206251A BR 0206251 A BR0206251 A BR 0206251A BR 0206251 A BR0206251 A BR 0206251A BR 0206251 A BR0206251 A BR 0206251A
Authority
BR
Brazil
Prior art keywords
methods
patient
evaluate
therapy
fti
Prior art date
Application number
BR0206251A
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of BR0206251A publication Critical patent/BR0206251A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODOS PARA AVALIAR E TRATAR LEUCEMIA". Métodos para tratamento de pacientes com leucemia incluem análise de perfis de expressão de genes de um paciente para determinar se o paciente tem probabilidades de responder ao tratamento com inibidor de farnesil transferase (FTI) e, opcionalmente, outros medicamentos terapêuticos. Os métodos também são úteis para monitoração da terapia do paciente e para seleção de um curso de terapia. Genes modulados em resposta ao tratamento com FTI são fornecidos e usados para formular os perfis.
BR0206251A 2001-10-30 2002-10-30 Métodos para avaliar e tratar leucemia BR0206251A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34093801P 2001-10-30 2001-10-30
US33899701P 2001-10-30 2001-10-30
US34008101P 2001-10-30 2001-10-30
US34101201P 2001-10-30 2001-10-30
PCT/US2002/034784 WO2003038129A2 (en) 2001-10-30 2002-10-30 Methods for assessing and treating leukemia

Publications (1)

Publication Number Publication Date
BR0206251A true BR0206251A (pt) 2004-06-15

Family

ID=27502594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206251A BR0206251A (pt) 2001-10-30 2002-10-30 Métodos para avaliar e tratar leucemia

Country Status (10)

Country Link
US (2) US20040110792A1 (pt)
EP (1) EP1478773B1 (pt)
JP (1) JP2005522990A (pt)
KR (1) KR20040065524A (pt)
AT (1) ATE373725T1 (pt)
BR (1) BR0206251A (pt)
CA (1) CA2451168A1 (pt)
DE (1) DE60222590T2 (pt)
MX (1) MXPA04004072A (pt)
WO (1) WO2003038129A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JP4898120B2 (ja) 2002-12-20 2012-03-14 アボット バイオセラピューティクス コーポレイション Ｇｐｒ６４に対する抗体とその利用法
US20050283854A1 (en) 2003-05-23 2005-12-22 Anton Krumm Recombinant vectors for use in position-independent transgene expression within chromatin
AU2004202980B2 (en) * 2003-07-01 2009-05-07 Veridex, Llc Methods for assessing and treating leukemia
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
WO2006124836A1 (en) * 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
MX2008002101A (es) * 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
ITRM20050475A1 (it) * 2005-09-19 2007-03-20 Univ Degli Studi Genova Sequenze trascritte da rna polimerasi iii tipo iii e loro uso.
US20080199873A1 (en) * 2006-12-04 2008-08-21 Anderson Mark G Companion diagnostic assays for cancer therapy
CA2680909A1 (en) * 2007-03-12 2008-09-18 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2008156613A1 (en) * 2007-06-12 2008-12-24 Schering Corporation Histone h2ax (hh2ax) biomarker for fti sensitivity
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2010062857A1 (en) 2008-11-26 2010-06-03 Allergan, Inc. Klk-13 antibody inhibitor for treating dry eye
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
JP6034784B2 (ja) 2010-07-28 2016-11-30 ジャンセン ダイアグノスティックス，エルエルシー ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
EA201890512A1 (ru) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
BR112019009000A2 (pt) 2016-11-03 2019-07-16 Kura Oncology Inc método para tratar um carcinoma refratário, método de tratamento de scchn, método de tratamento de carcinoma de células escamosas, método de tratamento para scc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US5968784A (en) * 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
WO2001055170A1 (en) * 2000-01-26 2001-08-02 Vanderbilt University Mob-5/hmob-5 as a cancer diagnostic marker
AU2001266587A1 (en) * 2000-05-17 2001-11-26 University Of South Florida Statistical image analysis

Also Published As

Publication number Publication date
US20070048782A1 (en) 2007-03-01
KR20040065524A (ko) 2004-07-22
DE60222590D1 (de) 2007-10-31
CA2451168A1 (en) 2003-05-08
DE60222590T2 (de) 2008-06-19
WO2003038129A3 (en) 2004-09-10
MXPA04004072A (es) 2004-09-06
JP2005522990A (ja) 2005-08-04
ATE373725T1 (de) 2007-10-15
EP1478773B1 (en) 2007-09-19
US20040110792A1 (en) 2004-06-10
EP1478773A2 (en) 2004-11-24
WO2003038129A2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
BR0206251A (pt) Métodos para avaliar e tratar leucemia
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
MXPA05005923A (es) Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
ATE403750T1 (de) Methoden und kompositionen zur bewertung von antikörper behandlungen
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
NO20052955L (no) Behandling av Huntingtons sykdom med EPA
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60228592D1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
BRPI0503418A (pt) prognóstico para malignidade hematológica
EP1565582A4 (en) METHODS FOR IDENTIFYING BREAST CANCER RISKS AND CORRESPONDING TREATMENTS
DE60212627D1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
DK1401413T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
ATE531813T1 (de) System zur überwachung einer bakteriellen tumorbehandlung
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
EP1502962A3 (en) Methods for assessing and treating cancer
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ORTHO-CLINICAL DIAGNOSTICS, INC. (US)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME SOLICITADO NA PETICAO NO 068643/RJ DE 09/12/2003.

B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: ORTHO-CLINICAL DIAGNOSTICS, INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.